Ocugen shares are trading lower. The company announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa.
Portfolio Pulse from Benzinga Newsdesk
Ocugen shares are trading lower after the company announced the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400, a gene therapy for retinitis pigmentosa.
June 20, 2024 | 3:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ocugen shares are trading lower following the announcement of the first patient dosed in its Phase 3 liMeliGhT clinical trial for OCU400, a gene therapy for retinitis pigmentosa.
The market reaction to the news of the first patient being dosed in the Phase 3 trial for OCU400 has been negative, leading to a drop in Ocugen's share price. This could be due to investor concerns about the trial's success or the financial implications of the trial.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100